Inhibition of angiogenesis as a strategy for tumor growth control.
Angiogenesis is a complex sequence of events leading to the formation of new capillaries. Although essential to maturation and wound healing, most angiogenesis in the adult is associated with pathological events, such as the development of solid tumors. One approach to the inhibition of angiogenesis is the antagonism of basic fibroblast growth factor, a major angiogenic protein. Evidence is reviewed to suggest that inhibiting angiogenesis results in the suppression of tumor growth.
Herblin
W F
WF
Du Pont Merck Pharmaceutical Company, Wilmington, DE.
Gross
J L
JL
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000098:blood supply / Q000473:pathology / Q000628:therapy; D016222:Fibroblast Growth Factor 2 / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000502:physiology; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000098:blood supply* / Q000473:pathology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D014183:Transplantation, Heterologous
D000906:Antibodies; D016222:Fibroblast Growth Factor 2